Most Read Articles
3 days ago
A recent study reports a mean growth rate of proximal aorta of about 0.1 mm/year in hypertensive patients with known aortic dilatation. In addition, those with increased rather than normal aortic z score have slower dilatation over time.
Tristan Manalac, 2 days ago
The coronavirus disease 2019 (COVID-19) appears to be more dangerous among cancer patients, who tend suffer more severe complications and faster disease progression, according to a new study.
01 Apr 2020
Knee osteoarthritis (OA), whether symptomatic or radiographic, contributes to an increased risk of all-cause mortality, with the risk increase from symptomatic knee OA partially attributed to its effect on disability and quality of life (QoL).
2 days ago
Cuff-based excess pressure (XSP) is modestly associated with carotid intima–media thickness independent of conventional risk factors, reveals a recent study.

Dupilumab safe, effective for eosinophilic oesophagitis

22 Jan 2020
Malaysians need to pay attention to gut health to prevent the onset of chronic diseases like diabetes and cancer

Dupilumab may be a potential treatment for eosinophilic oesophagitis (EoE), leading to reduced dysphagia and better control of the histologic features of the disease, a recent trial has found.

EoE patients were randomly assigned to receive weekly subcutaneous injections of 300-mg dupilumab (n=23; mean age, 33.1±8.70 years; 57 percent male) or placebo (n=24; mean age, 36.1±12.75 years; 42 percent male). The 10-week change in the Straumann Dysphagia Instrument (SDI) patient-reported outcome (PRO) scores was the primary outcome. Other endpoints included histologic and endoscopic features, safety and oesophageal distensibility. The trial lasted for 12 weeks.

Significant improvements in SDI PRO scores were reported by week 10 in the dupilumab vs placebo group (p=0.0304). Patients who received the active treatment experienced improvements as early as week 1. This finding was robust to sensitivity analyses.

Moreover, all 23 patients who were given dupilumab showed lower oesophageal intraepithelial eosinophil counts after 12 weeks. This represented a significant advantage relative to placebo (p<0.0001).

These effects did not come with excessive safety issues, and dupilumab was generally well-tolerated over 12 weeks of treatment. Nonserious erythema (35 percent) and nasopharyngitis (17 percent) were the most common treatment-emergent adverse events (TEAEs). One patient in the dupilumab arm had to discontinue treatment due to a TEAE.

There were no deaths or serious TEAEs deemed related to the test medication.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
A recent study reports a mean growth rate of proximal aorta of about 0.1 mm/year in hypertensive patients with known aortic dilatation. In addition, those with increased rather than normal aortic z score have slower dilatation over time.
Tristan Manalac, 2 days ago
The coronavirus disease 2019 (COVID-19) appears to be more dangerous among cancer patients, who tend suffer more severe complications and faster disease progression, according to a new study.
01 Apr 2020
Knee osteoarthritis (OA), whether symptomatic or radiographic, contributes to an increased risk of all-cause mortality, with the risk increase from symptomatic knee OA partially attributed to its effect on disability and quality of life (QoL).
2 days ago
Cuff-based excess pressure (XSP) is modestly associated with carotid intima–media thickness independent of conventional risk factors, reveals a recent study.